- Home
- JBDI vs CMMB Comparison
JBDI vs CMMB Comparison
Compare JBDI & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBDI | CMMB |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | Singapore | Israel |
| Employees | 104 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 13.2M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | JBDI | CMMB |
|---|---|---|
| Price | $0.67 | $1.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 43.4K | ★ 70.5K |
| Earning Date | 05-07-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $50.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.52 | $0.87 |
| 52 Week High | $2.28 | $3.86 |
Technical Indicators
Market Signals| Indicator | JBDI | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 53.81 |
| Support Level | $0.61 | $1.48 |
| Resistance Level | $1.05 | $2.80 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 17.15 | 34.99 |
Price Performance
Historical ComparisonAbout JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. It's in the trading of reconditioned and recycling containers in Singapore and the Southeast Asia region. The company offers reconditioning and recycling drums, including open top drums, metal drums, plastic drums, plastic carboys, and intermediate bulk containers, as well as new drums, and collects waste drums and related products. It serves solvent, chemical, petroleum, and edible product oil industries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.